Literature DB >> 29292333

Two-stage revision for the culture-negative infected total hip arthroplasty : A comparative study.

M S Ibrahim1, H Twaij2, F S Haddad3.   

Abstract

AIMS: Periprosthetic joint infection (PJI) remains a challenging complication following total hip arthroplasty (THA). It is associated with high levels of morbidity, mortality and expense. Guidelines and protocols exist for the management of culture-positive patients. Managing culture-negative patients with a PJI poses a greater challenge to surgeons and the wider multidisciplinary team as clear guidance is lacking. PATIENTS AND METHODS: We aimed to compare the outcomes of treatment for 50 consecutive culture-negative and 50 consecutive culture-positive patients who underwent two-stage revision THA for chronic infection with a minimum follow-up of five years.
RESULTS: There was no significant difference in the outcomes between the two groups of patients, with a similar rate of re-infection of 6%, five years post-operatively. Culture-negative PJIs were associated with older age, smoking, referral from elsewhere and pre-operative antibiotic treatment. The samples in the culture-negative patients were negative before the first stage (aspiration), during the first-stage (implant removal) and second-stage procedures (re-implantation).
CONCLUSION: Adherence to strict protocols for selecting and treating culture-negative patients with a PJI using the same two-stage revision approach that we employ for complex culture-positive PJIs is important in order to achieve control of the infection in this difficult group of patients. Cite this article: Bone Joint J 2018;(1 Supple A)100-B:3-8. ©2018 The British Editorial Society of Bone and Joint Surgery.

Entities:  

Keywords:  Culture negative infection; Hip arthroplasty; Total hip replacement; Two-stage revision

Mesh:

Year:  2018        PMID: 29292333      PMCID: PMC6424436          DOI: 10.1302/0301-620X.100B1.BJJ-2017-0626.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


The United Kingdom’s National Joint Registry (NJR) has recorded almost 800 000 primary total hip arthroplasties (THA) since 2003.[1] Of these, 20 926 were revisions and 2889 as a consequence to periprosthetic joint infection (PJI),[1] which can be a catastrophic complication.[2] This may be an underestimate of the true burden.[3,4] An increase in the number of revision cases is associated with increased costs to the National Health Service[1] with far greater costs than are anticipated, or funded, for infected cases.[5] Treating infection involves identifying the organism and administering the appropriate antibiotics. Clear guidance and protocols are available for the management of culture-positive patients.[6] Culture-negative PJI, however, remains a challenging condition to manage, lacking guidelines or protocols. These cases account for between 5% and 12 % of all PJIs[7,8] and have variable outcomes. These patients are usually frail, with many comorbidities, soft tissue problems, communicating sinuses (tracts communicating from skin to prosthesis) and bone loss. Two-stage revision arthroplasty is the most commonly undertaken form of treatment, being more effective than a single-stage revision.[9,10] Single-stage procedures are contraindicated in culture- negative patients due to a lack of identified organism.[11] It has been suggested that the characteristic patient with a culture-negative PJI is a man aged > 65 years with many comorbidities and a body mass index (BMI) of > 25 kg/m2.[7] However, the literature lacks specific analysis of the associated risk factors. This study aims to compare outcomes between culture-negative and culture-positive PJIs in a prospectively compiled database of two-stage revision arthroplasties, identifying the risk factors in these patients.

Patients and Methods

Consecutive patients who underwent a two-stage revision THA for infection between 2007 and 2012 with a minimum follow-up of five years were recorded from the database. Two groups were identified for this study, those who had negative culture results prior to the first stage procedure and those in whom a specific micro-organism was identified. Patients with acute PJI (within six weeks of implantation), those with metal-on-metal bearing surfaces and those who underwent a single-stage procedure were excluded.[12] Routine assessment included a thorough history and examination with blood tests, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white cell count (WCC). The hip was aspirated under fluoroscopic guidance and the fluid was sent to the laboratory for testing. Routine analysis included extended cultures, gram stain, Coxiella and Brucella serologies, acid-fast bacilli, fungal and sensitivity tests, and polymerase chain reaction (PCR) in a few patients. Sonification of retrieved components is not used routinely in our unit. As part of our protocol, antibiotic treatment is stopped four weeks before the aspiration is undertaken, as described by Oussedik et al[13] in 2010. Biopsy was also performed to increase sensitivity and accuracy. This should be in combination with aspiration.[14] Patients with a culture-negative PJI were identified at this time, and the diagnosis of PJI in these patients was made based on criteria defined by Berbari et al[8] in 2007. This includes a failure to isolate micro-organisms following standard aerobic and anaerobic microbiological techniques performed on blood cultures, synovial fluid and samples of periprosthetic tissue and one or more of the criteria listed in Table I. Definition of culture-negative periprosthetic joint infection (Berbari et al)[8] Patients were separated into single or two-stage treatment regimes according to a standardised protocol for PJIs, based on criteria which have been previously described.[15] Those with contraindications for single-stage revision had two-stage surgery[13] (Table II). Contraindications for single-stage revision All procedures were performed by a single surgeon (FSH) in a tertiary centre. The first stage involves open, aggressive debridement with removal of components and cement. Between three to five tissue samples are taken with separate sterile instruments to limit the risk of contamination[16] and sent for urgent microbiology and histology. Microbiology culture was negative in these samples, but some histology results were positive for inflammation (Table III). Positive diagnostic criteria identified in the culture-negative group The hip is irrigated with a mixture of hydrogen peroxide and Betadine solutions (Videne, Ecolab Ltd, Swindon, United Kingdom), followed by thorough lavage. The wound is soaked in aqueous Betadine and the edges approximated. The patient is re-draped and the surgical team rescrubs prior to implanting a temporary articulating antibiotic loaded cement spacer with new, clean instruments. The spacer normally contains 3 g vancomycin and 2 g gentamicin per sachet of Palacos R (Heraeus Medical, Wehrheim, Germany), providing broad spectrum cover for organisms commonly encountered with PJIs whilst discouraging the development of resistant strains.[17] The management of all patients is discussed in a multidisciplinary meeting prior to starting specific antibiotics according to a strict protocol.[18] Further discussions follow after obtaining any samples at any stage and the antibiotic programme is changed accordingly. Patients are discharged when they are deemed safe mobilising partially weight-bearing. Following the first stage, all patients usually receive gentamycin and teicoplanin for at least six weeks unless directed otherwise by the multidisciplinary team. They are regularly reviewed to monitor the control of infection, and if there is any doubt about eradication the first stage is repeated until the infection is under control.[18] The decision to proceed to the second stage is determined by the clinical and biochemical response, looking at wound healing and inflammatory and nutritional markers. Once inflammatory markers show no evidence of infection, antibiotic treatment is stopped for two weeks when the patient is reviewed again. Once satisfactory, the second stage can proceed. This involves removal of the spacer and cement mantle, piecemeal if necessary to preserve bone stock. More samples are obtained at this point and appropriate cemented components are re-implanted. Allograft may be used in patients with severe bone loss.[19] At this stage, once more, all samples in the culture-negative group were negative. It is important to note that all samples in the culture-negative cohort were negative before the first stage (during aspiration), during first-stage (implant removal) and second-stage (re-implantation). All patients were then reviewed at six weeks, six months, one year and yearly thereafter looking carefully for symptoms and signs of infection and recording inflammatory markers (ESR, CRP and WCC). Functional outcomes were assessed using the Harris Hip Scores (HHS).[20] Plain radiographs, including anteroposterior (AP) and lateral views, were obtained at each time to identify radiographic signs of infection such as progressive lucencies using radiological criteria outlined by Johnston et al.[21] The eradication of infection is defined as the absence of clinical, serological, and radiographic signs at any subsequent time. The Musculoskeletal Infection Society (MSIS) criteria were used at the final review to confirm the control of infection.[16,22] Failure was defined as any major operation performed in any patient for the control of infection, including further two-stage revision, excision arthroplasty, arthrodesis, amputation or the need for long-term antibiotic suppression. The groups were compared using the following variables: age, gender, BMI, smoking, alcohol, American Society of Anesthesiology (ASA) grade,[23] diabetes, primary diagnosis (rheumatoid or osteoarthritis), type of THA (primary or revision), type of fixation (cemented or cementless), source of referral (from our institution or from elsewhere), the presence of a sinus and vascular disease.

Statistical analysis

A chi-squared test was employed to identify differences between categorical variables and outcomes. The Mann-Whitney U test and two-sample student t-tests were used to compare continuous variables and outcomes between the two groups using SPSS version 20 (IBM, Armonk, New York). A multiple logistic regression analysis was performed to identify the independent influence of each variable in Table IV on developing culture-negative samples in PJI in a forward stepwise model. A p-value of < 0.05 was considered significant. Comparison of variables between culture-negative and culture-positive groups ASA, American Society of Anesthesiologists Departmental approval was obtained to conduct this study.

Results

There were 50 consecutive patients in each group. The mean age was 74 years (43 to 88) in the culture-negative group and 71 years (41 to 83) in the culture-positive group. Both groups had more women than men. There were no significant demographic differences between the groups (Table IV). Most of the micro-organisms isolated in the culture-positive group were gram-positive bacteria (Table V). Isolated micro-organisms for the culture-positive group There were no differences in functional outcomes between the groups. The mean Harris hip scores (HHS) were 83 (sd 9) and 85 for the culture-negative and culture-positive group respectively; this difference was not statistically significant (p = 0.34). Three patients in the culture-negative group and four in the culture-positive group required further revision surgery but again this difference was not statistically significant (p = 0.14). Five patients in the culture-negative group had several first-stage procedures compared with two in the culture-positive group, but this was not significant (p = 0.09). There were no other differences in the complications (Table VI). The rate of re-infection at five years was 6% for both groups. Staphylococcus epidermidis was cultured at a further staged revision in the three patients with a recurrent infection. In the culture- positive group, two patients had polymicrobial cultures in their staged revision and one had staphylococcus epidermidis. The fourth patient was revised due to multiple dislocations and instability and had a diagnosis of infection in the last operation and remains as such. Outcomes of culture-negative and culture-positive groups *p-value calculated using Mann-Whitney U test †p-value calculated using chi-squared test HHS, Harris Hip Score Univariate analysis identified the following risk factors for culture-negative samples: age, referral from elsewhere, smoking and pre-operative antibiotics these were entered into multivariate logistic regression model to reveal preoperative antibiotics and referral from elsewhere as the most significant risk factors for culture-negative group (Table VII). Multivariate analysis on significant risk factors from univariate analysis *p-values calculated using multivariate logistic regression analysis Five patients in the culture-negative group were lost to follow-up after the five-year mark, three in the culture-positive group were lost after the fourth year but they have not had further surgery. It is possible that these patients may have passed away and therefore lost to follow-up.

Discussion

We found no significant differences in outcomes between culture-negative and culture-positive patients following two-stage revision THA at medium term follow-up. The rate of re-infection for both culture-negative and culture-positive groups was 6% five years post-operatively, in line with other published studies dealing with culture-negative PJIs.[8,24] There were no significant differences in the outcomes between both groups, this is in line with other published studies.[24] Choi et al,[25] on the other hand, found that culture-negative patients (n = 40) have a better rate of infection control (p = 0.006) than culture-positive patients (n = 132) with mean follow up of four years, but this cohort included total knee replacements as well as THAs; our study is concerned with THA only. In our study, the selection of patients was also different as straight-forward cases were treated with a single-stage revision, and the more complex cases with more virulent organisms underwent two-stage revision. Culture-negative patients were treated identically to complex, culture-positive patients with aggressive debridement and antibiotics recommended by multidisciplinary collaboration.[18] This should be taken into account when comparing the rate of control of infection in this study with others (Table VIII). Rate of infection-free survival for studies dealing with culture-negative infected total hip arthroplasties undergoing two-stage revision These findings suggest that more extensive, invasive and expensive investigations such as arthroscopic sampling following aspiration and biopsy,[27] are unnecessary, as these patients should be treated as having a complex culture-positive PJI. They should not be treated with a single-stage revision.[11] There are many risk factors contributing to infection in general and these are shared for the culture-negative and culture-positive groups. These include immunocompromised patients and those with multiple comorbidities.[28-30] Many authors have described the risk factors, including age, gender, comorbidities and BMI, associated with culture-negative PJI in general, usually with a mixture of arthroplasties of the hip, knee and shoulder.[7,31] In our study, gender and BMI were not significant factors but age was identified as a risk factor for culture-negative PJI. Smoking is a known risk factor for culture-negative PJI in several studies[7,31] and this was replicated in our study. Many authors have reported that taking antibiotics within three months of obtaining samples was a significant risk factor for culture-negative PJI,[7,25,26,28-30] this was also replicated in our study, although we only included THAs. Although the risk factors are well described in the literature, we identified a factor not previously considered: referral from elsewhere. This may be related to the pre-operative use of antibiotics, as most of these patients were referred several months after the start of infection. Patients from our institution all had positive cultures, probably as strict protocols are in place for the management of a PJI. It is difficult to control the use of antibiotics prior to specialist intervention. However, educating healthcare providers may reduce this; specifically, general practitioners and emergency medicine doctors. In spite of extended cultures and PCR, no organism was identified at any point on the culture-negative patients, in contrast to Bereza et al[32] who were able to identify organisms at a later stage, or following further investigations such as sonification and PCR testing. Limitations of this study include the small sample size for both groups and the lack of randomisation. The consecutive nature of the cohort of patients helps to avoid selection bias. Longer follow up would improve the identification of rates of recurrent infection. However, most studies in the literature have a similar follow-up. In conclusion, we found that in spite of negative cultures in patients with PJI after THA, effective treatment is achievable by treating these patients as if they were complex culture-positive patients with a two-stage revision and strict protocols. The outcomes with such management are similar to the management of culture-positive patients. Take home message: - Aseptic joint infection is a complex problem and should be considered as such. - Culture-negative infections can be eradicated with a two-stage revision approach, following strict protocols. - Outcomes of culture-negative PJIs are similar to complex patients with positive cultures. -Reducing culture-negative infections can be achieved with education regarding antibiotic usage in the community
Table I

Definition of culture-negative periprosthetic joint infection (Berbari et al)[8]

(i) Periprosthetic purulence observed at the time of operation
(ii) Histopathological features consistent with acute inflammation
(iii) Elevated synovial white cell count (> 1.7 × 103 /μL3) or elevated synovial neutrophil (PMN) percentage (> 65% PMNs) or
(iv) Sinus track in direct communication with the joint
Table II

Contraindications for single-stage revision

Local factors
Significant tissue compromise
Significant bone loss
Peripheral vascular disease
Host factors
Immunosuppression
Concurrent sepsis
Systemic disease
Reinfection
Organism factors
Multi-resistant organisms
Polymicrobial infection
Commensals
Unusual resistance profiles
Table III

Positive diagnostic criteria identified in the culture-negative group

CriteriaPatients (n)
Sinus2
Histopathology (showing inflammation)28
Periprosthetic purulence observed at the time of operation39
Table IV

Comparison of variables between culture-negative and culture-positive groups

VariablesCulture –ve group (n = 50)Culture +ve group (n = 50)
Mean age (yrs) (range; sd)74 (43 to 88; 8)71 (41 to 83; 7)
Gender (female:male)27:2329:21
Mean body mass index, kg/m2 (sd)32.6 (7.3)34.1 (5.3)
Smokers1619
Alcohol > weekly recommended units115
ASA grade, patient (n)1, 01, 0
2, 192, 22
3, 343, 34
4, 74, 4
Diabetes mellitus75
Primary diagnosis
Rheumatoid arthritis73
Osteoarthritis4347
Type of total hip arthroplasty
Primary3229
Revision1821
Type of fixation
Cemented2922
Cementless2128
Source of referral
In-house84
Referral from elsewhere4246
Sinus
Yes29
No4841
Vascular disease
Yes117
No3943
Pre-operative Harris Hip Scores[20] (range)44 (30 to 68)40 (27 to 70)

ASA, American Society of Anesthesiologists

Table V

Isolated micro-organisms for the culture-positive group

MicroorganismsPatients (n)
Gram-positive30
Gram-negative13
Anaerobes9
Mycobacterium0
Polymicrobial8
Table VI

Outcomes of culture-negative and culture-positive groups

Culture –ve group (n = 50)Culture +ve group (n = 50)p-value
Mean post-operative HHS83 (sd 9)85 (sd 8)0.34*
Further revision340.14
Repeat first stage procedures520.09
Dislocation430.062
Fracture110.24
Recurrent infection330.19

*p-value calculated using Mann-Whitney U test †p-value calculated using chi-squared test HHS, Harris Hip Score

Table VII

Multivariate analysis on significant risk factors from univariate analysis

FactorUnivariate (p- value)Multivariate results (odds ratio)Multivariate results (p-value)*
Age (yrs)0.0032.40.32
Smoking0.0372.10.56
Pre-operative antibiotics0.0024.10.003
Referral from elsewhere0.00163.10.001

*p-values calculated using multivariate logistic regression analysis

Table VIII

Rate of infection-free survival for studies dealing with culture-negative infected total hip arthroplasties undergoing two-stage revision

StudyRate of control of infection (%)Mean follow-up (yrs)
Berbari et al[8]945
Malekzadeh et al[26]784.6
Bejon et al[6]835.7
Huang et al[24]703.9
Choi et al[25]854
Our study945
  30 in total

Review 1.  The treatment of the infected hip replacement. The complex case.

Authors:  F S Haddad; B A Masri; D S Garbuz; C P Duncan
Journal:  Clin Orthop Relat Res       Date:  1999-12       Impact factor: 4.176

2.  New definition for periprosthetic joint infection.

Authors: 
Journal:  J Arthroplasty       Date:  2011-12       Impact factor: 4.757

3.  Prior use of antimicrobial therapy is a risk factor for culture-negative prosthetic joint infection.

Authors:  Davud Malekzadeh; Douglas R Osmon; Brian D Lahr; Arlen D Hanssen; Elie F Berbari
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

4.  New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society.

Authors:  Javad Parvizi; Benjamin Zmistowski; Elie F Berbari; Thomas W Bauer; Bryan D Springer; Craig J Della Valle; Kevin L Garvin; Michael A Mont; Montri D Wongworawat; Charalampos G Zalavras
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

5.  Culture-negative periprosthetic joint infection does not preclude infection control.

Authors:  Ronald Huang; Chi-Chien Hu; Bahar Adeli; Javad Mortazavi; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

Review 6.  Antibiotic-impregnated PMMA hip spacers: Current status.

Authors:  Konstantinos Anagnostakos; Oliver Fürst; Jens Kelm
Journal:  Acta Orthop       Date:  2006-08       Impact factor: 3.717

7.  Outcomes of revision total hip replacement for infection after grading according to a standard protocol.

Authors:  S I S Oussedik; M B Dodd; F S Haddad
Journal:  J Bone Joint Surg Br       Date:  2010-09

8.  Is there a role for tissue biopsy in the diagnosis of periprosthetic infection?

Authors:  Geert Meermans; Fares S Haddad
Journal:  Clin Orthop Relat Res       Date:  2010-02-04       Impact factor: 4.176

9.  Culture-negative prosthetic joint infection.

Authors:  Elie F Berbari; Camelia Marculescu; Irene Sia; Brian D Lahr; Arlen D Hanssen; James M Steckelberg; Rachel Gullerud; Douglas R Osmon
Journal:  Clin Infect Dis       Date:  2007-09-26       Impact factor: 9.079

10.  Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology.

Authors:  P Bejon; A Berendt; B L Atkins; N Green; H Parry; S Masters; P McLardy-Smith; R Gundle; I Byren
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

View more
  13 in total

1.  Do Culture Negative Periprosthetic Joint Infections Remain Culture Negative?

Authors:  Beverly L Hersh; Neel B Shah; Scott D Rothenberger; Jason P Zlotnicki; Brian A Klatt; Kenneth L Urish
Journal:  J Arthroplasty       Date:  2019-06-28       Impact factor: 4.757

Review 2.  Diagnostic Value of Next-Generation Sequencing in Periprosthetic Joint Infection: A Systematic Review.

Authors:  Yuchen Tang; Dacheng Zhao; Shenghong Wang; Qiong Yi; Yayi Xia; Bin Geng
Journal:  Orthop Surg       Date:  2021-12-21       Impact factor: 2.071

3.  Culture-negative Peri-prosthetic Joint Infection after Total Hip Arthroplasty Treatment Protocol and Outcomes in Acute and Chronic Cases.

Authors:  Germán Garabano; Alan Maximiliano Gessara; Cesar Angel Pesciallo; Jorge Martinez; Hernán Del Sel
Journal:  Arch Bone Jt Surg       Date:  2022-09

4.  Characteristics and outcomes of culture-negative prosthetic joint infections from the Prosthetic Joint Infection in Australia and New Zealand Observational (PIANO) cohort study.

Authors:  Sarah Browning; Laurens Manning; Sarah Metcalf; David L Paterson; James O Robinson; Benjamin Clark; Joshua S Davis
Journal:  J Bone Jt Infect       Date:  2022-09-20

5.  The EBJIS definition of periprosthetic joint infection.

Authors:  Martin McNally; Ricardo Sousa; Marjan Wouthuyzen-Bakker; Antonia F Chen; Alex Soriano; H Charles Vogely; Martin Clauss; Carlos A Higuera; Rihard Trebše
Journal:  Bone Joint J       Date:  2021-01       Impact factor: 5.082

6.  Do Culture-Negative Periprosthetic Joint Infections Have a Worse Outcome Than Culture-Positive Periprosthetic Joint Infections? A Systematic Review and Meta-Analysis.

Authors:  Marie Reisener; Carsten Perka
Journal:  Biomed Res Int       Date:  2018-07-12       Impact factor: 3.411

7.  Periprosthetic Joint Infection Caused by Gram-Positive Versus Gram-Negative Bacteria: Lipopolysaccharide, but not Lipoteichoic Acid, Exerts Adverse Osteoclast-Mediated Effects on the Bone.

Authors:  Mei-Feng Chen; Chih-Hsiang Chang; Chih-Chien Hu; Ying-Yu Wu; Yuhan Chang; Steve W N Ueng
Journal:  J Clin Med       Date:  2019-08-23       Impact factor: 4.241

8.  A sophisticated antibiotic-loading protocol in articulating cement spacers for the treatment of prosthetic joint infection: A retrospective cohort study.

Authors:  Chuang Yang; Jin Wang; Zhifei Yin; Qiaojie Wang; Xianlong Zhang; Yao Jiang; Hao Shen
Journal:  Bone Joint Res       Date:  2019-12-03       Impact factor: 5.853

Review 9.  Culture-negative periprosthetic joint infections.

Authors:  Jeya Palan; Ciaran Nolan; Kostas Sarantos; Richard Westerman; Richard King; Pedro Foguet
Journal:  EFORT Open Rev       Date:  2019-10-07

10.  Low-dose vancomycin-loaded cement spacer for two-stage revision of infected total hip arthroplasty.

Authors:  Ömür Çağlar; Mazhar Tokgözoğlu; Rahmi C Akgün; Bülent Atilla
Journal:  Jt Dis Relat Surg       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.